Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2014 on Tuesday, April 29, 2014 at 8:00 a.m. ET. Boston Scientific Corporation (NYSE:BSX) shares after opening at $13.55 moved to $13.65 on last trade day and at the end of the day closed at $13.62. Company price to sales ratio in past twelve months was calculated as 2.52 and price to cash ratio as 83.07. Boston Scientific Corporation (NYSE:BSX) showed a positive weekly performance of 2.71%.
The decision could postpone generic competition to Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)’s highest selling drug and would also additionally change the way patent appeals are managed. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) shares advanced 0.44% in last trading session and ended the day on $53.07. TEVA return on equity ratio is recorded as 5.70% and its return on assets is 2.70%. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) yearly performance is 38.56%.
Gilead Sciences, Inc. (NASDAQ:GILD) on Mar. 28 announced that it has elected to settle its conversion obligations in connection with any 1.00% Senior Convertible Notes due 2014 (the “Notes”) submitted for conversion on or after February 1, 2014 entirely in cash. Gilead Sciences, Inc. (NASDAQ:GILD) shares moved up 3.92% in last trading session and was closed at $73.64, while trading in range of $72.14 – $73.88. Gilead Sciences, Inc. (NASDAQ:GILD) year to date (YTD) performance is -1.94%.
Mylan Inc. (NASDAQ:MYL) announced that yesterday the Supreme Court of the United States granted certiorari in Mylan’s patent litigation against Teva relating to Mylan’s Abbreviated New Drug Application (ANDA) for glatiramer acetate (Copaxone). Mylan Inc. (NASDAQ:MYL) weekly performance is -2.76%. On last trading day company shares ended up $49.31. Mylan Inc. (NASDAQ:MYL) distance from 50-day simple moving average (SMA50) is -0.32%. Analysts mean target price for the company is $60.47.
Leave a Reply